The individualization of treatment based on molecular markers
Tóm tắt
Recent developments have revealed various decisive discoveries in individualized oncology for many different entities—the individualization of treatment based on molecular markers representing just one of those milestones. The implication of epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitor (TKI) treatment, the definition of the HER2 status in breast cancer and the application of the KRAS mutation analysis in colorectal cancer are examples for this development. All these activities have also been the major focus at the Cancer Research Institute in St. Petersburg, where I worked for many years. Within the last years, a growing connection between basic research activities and clinical application can be observed.
Tài liệu tham khảo
Moiseyenko VM, Danilov AO, Baldueva IA, Danilova AB, Tyukavina NV, Larin SS, et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors. Ann Oncol. 2005;16(1):162–8.
Imyanitov EN, Moiseyenko VM. Invited critical review. Molecular-based choice of cancer therapy: realities and expectations. Clinica Chimica Acta. 2007;379:1–13.
Moiseyenko VM, Procenko SA, Levchenko EV, Barchuk AS, Moiseyenko FV, Iyevleva AG, et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie. 2010;33(5):231–8.
Levchenko EV, Moiseyenko VM, Matsko DE, Iyevleva AG, Ivantsov AO, Yargnian SM, et al. Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases. Onkologie. 2009 Nov;32(11):674–7.
Suspitsin EN, Levchenko EV, Moiseyenko FV, Ivantsov AO, Radzhabova SA, Matsko DE, et al. Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules? Onkologie. 2011;34(10):559–60.
Iyevleva AG, Novik AV, Moiseyenko VM, Imyanitov EN. EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol. 2009 Sep–Oct;27(5):548–50.
Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 2011 Aug 6;9(1):2–16.
Abysheva SN, Iyevleva AG, Efimova NV, Mokhina YB, Sabirova FA, Ivantsov AO, et al. KIT mutations in Russian patients with mucosal melanoma. Melanoma Res. 2011 Dec;21(6):555–9.